Ratings ALK-Abelló A/S

Equities

ALK B

DK0061802139

Real-time Estimate Cboe Europe Other stock markets 08:13:41 2024-05-21 am EDT			5-day change	1st Jan Change
153.8 ^DKK	+1.18%		-0.26%	+52.27%

May. 03	Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024
May. 02	ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
The company is in a robust financial situation considering its net cash and margin position.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.47 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ALK-ABELLÓ A/S	+52.27%	4.89B	B+
ELI LILLY AND COMPANY	+34.35%	705B	C+
NOVO NORDISK A/S	+30.87%	583B	B
JOHNSON & JOHNSON	-3.49%	364B	C+
MERCK & CO., INC.	+20.15%	332B	B-
ABBVIE INC.	+6.19%	291B	C+
ASTRAZENECA PLC	+15.15%	238B	B+
ROCHE HOLDING AG	-3.44%	210B	A+
NOVARTIS AG	+10.06%	209B	B-
AMGEN INC.	+9.21%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes